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ABSTRACT 
Differentiating erythroid cells execute a unique gene expression program that insures synthesis of 
the appropriate proteome at each stage of maturation. Standard expression microarrays provide 
important insight into erythroid gene expression, but cannot detect qualitative changes in transcript 
structure, mediated by RNA processing, that alter structure and function of encoded proteins. We 
analyzed stage-specific changes in the late erythroid transcriptome via use of high res~lution 
microarrays that detect altered expression of individual exons. Ten differentiation-associated changes in 
erythroblast splicing patterns were identified, including the previously known activation of proteii 4.1R 
exon 16 splicing. Six new alternative splicing switches involving enhanced inclusion of internal 
cassette exons were discovered, as well as three changes in use of alternative first exons. All of these 
erythroid stage-specific splicing events represent activated inclusion of authentic annotated exons, 
suggesting they represent an active regulatory process rather than a general loss of splicing fidelity. The 
observation that three of the regulated transcripts encode RNA binding proteins (SNRP70, HNkPLL, 
MBNL2) may indicate significant changes in the RNA processing machinery of late erythroblasts. 
Together these results support the existence of a regulated alternative pre-mRNA splicing program that 
is critical, for Late erythroid differentiation. ~ 
INTRODUCTION 
Differentiation of erythroid progenitors into mature red cells requires a carefully orchdstrated 
gene expression program to insure synthesis of the appropriate stage-specific proteome as the cells 
become progressively more specialized. Previous studies of erythroid gene expression have focused 
predominantly on quantitative or semi-quantitative assays including Western and Northern blotting, 
proteomic analysis, cDNA cloning, and microarray analysis. Together these studies have provided 
considerable insights into the late erythroid gene expression program. I 
However, gene-level expression analysis cannot identify important qualitative changes in 
erythroid gene expression predicted to result fiom alternative pre-mRNA processing pathways. 
Exclusion or inclusion of individual exons can substantially alter the structure and function of the 
encoded protein isoforms independent of changes in transcript expression levels. Given that the 
majority of genes in the human genome exhibit alternative splicing (e.g., ref. 1,2), and that alternative 
splicing pathways may be regulated during differentiation and development, it is likely that stage- 
specific alternative splicing "switches" play an important role in modulating protein function during 
erythroid differentiation. Such changes in erythroid transcript structure may be regulated at the 
transcriptional level in the case of alternative first exons3, or at the pre-mRNA splicing level in the case 
of internal exons4. To further understand the erythroid gene expression program, the erythroid 
transcriptome will need to be explored at different stages of erythropoiesis and at the resolution of 
individual exons. 
The best-studied example of regulated pre-mRNA splicing in erythroid cells is the stage-specific 
splicing switch of protein 4.1R exon 16. Alternative exon 16 is tightly regulated such that it is excluded 
in early erythroid progenitor cells, but efficiently included in late erythroblasts5". This splicing switch 
3 
is functionally important: exon 16 inclusion leads to synthesis of 4.1R protein isoforms with high 
affinity for spectrin and actin, and increased ability to mechanically stabilize the erythroid membrane7-9. 
Mechanistically, the splicing switch is regulated at least in part by changes in expression of antagonistic 
splicing factors, in particular, a decrease in expression of the splicing inhibitory factor hnRNP A1 
relative to that of stimulatory factors Fox-2 q d  $ F ~ / A S F ' ~ - ~ ~ .  It seems reasonable to propose that these 
changes in splicing factor activity would regulate not only protein 4.1R pre-mRNA splicing, but also a 
subset of other alternative splicing events that together may constitute an erythroid alternative splicing 
program. 
To explore the hypothesis that alternative splicing switches in other erythroid transcripts are 
executed during late erythropoiesis, we have undertaken a genome-wide expression analysis of 
1,14,15 
erythroblast transcripts at the level of individual exons. We used Affymetrix exon microarrays to 
identify erythroid stage-specific changes in exon expression, using RNA isolated from basophilic 
versus orthochromatic erythroblasts differentiated in vitro from human CD34+ erythroid progenitors'6- 
18.  Candidate alternative splicing events identified by microarray analysis were further validated by RT- 
PCR. Together these experiments revealed a number of internal alternative exons that exhibit 
significant changes in splicing efficiency, as well as differential expression of several alternative first 
exons that suggest changes in transcriptional promoter usage. These results suggest that an erythroid 
splicing program mediates stage-specific changes in transcript (and ultimately protein) structure and 
I 
function that likely are critical for proper erythropoiesis. 
MATERIALS AND METHODS 
Cell Isolation and Culture 
An in vitro primary culture system was employed to generate cells at different stages of human 
erythroid differentiation16. The culture system used was CD34-positive early hematopoietic progenitors 
isolated from growth factor mobilized peripheral blood (purchased from ALL Cells, Berkeley, CA) to 
promote the erythroid differentiation program. The culture media contained 15% FCS, 15% human AB 
serum, Iscove's modified Dulbecco's medium (IMDM), 10ng/ml IL-3, 2 units ml Epo, and 50 nglml 
SCF. SCF was gradually decreased, and IL-3 was not added after day 3. Cells were collected at day 7, 
10, and 14, which respectively correspond to basophilic (early), polychmmatic (intermediate), and 
orthochromatic (late) erythroblasts. 97-99% of these cells were erythroid as determined by flow 
cytometry for glycophorin A and CD71 (Figure 1A). 
Total RNA extraction and Sample Preparation 
Total cellular RNA was extracted from each culture at early (day 7), intermediate (day lo), and late (day 
14) stages of differentiation. Alpha- and beta-globin mRNAs were depleted from the RNA samples using 
GLOB IN^^^^^^^ Kit (Ambion, Inc.). 1 pg of total globin-depleted RNA was used to subtract ribosomal 
RNA using the ~ i b o m i n u s ~ ~  HumanIMouse Transcriptome Isolation kit (Invitrogen). Globin- and 
ribosomal RNA-depleted RNA was amplified and labeled for the exon array hybridization according to 
the Affymetrix WT Sense Target Labeling Assay Manual 
(http://affymetrix.com/products/arrays/specific/hugene~1~O~st/hugene~reagent~instrtrsolution.affx. The 
GenechipTM Hybridization Oven 320 and the GenechipTM Fluidics Station 450 were used for the 
hybridization and washing, respectively. The GenechipTM Scanner 3000 was used for scanning. 
Exon Array Analysis 
In order to identify candidate alternative splicing switches in differentiating erythroid cells, we assessed 
genome-wide changes in exon expression using two platforms: the Affymetrix Human Exon 1.0 ST 
,4rray1 and a non-commercial exon junction array (described below). The commercial Human Exon 1.0 
ST array was designed to be as inclusive as possible; it contains probes for virtually all known and 
predicted exons in the human genome and has the potential to discover novel splicing events1. In 
contrast, the junction array focuses on a smaller set of well-annotated exons and includes probes not 
only to each exon, but also to exon-exon junctions. This latter feature provides additional information 
that aids in predicting splicing differences between RNA samples, since a change in alternative sblicing 
should yield reciprocal changes in intensity of junction probes for the exon skipping and exon inclusion 
event, respectively. 
For the Human Exon 1.0 ST array, comparison of exon expression patterns in early verAus late 
erythroblasts was performed using XRAY software, version 2.5 Excel Add-In (Biotique Systems, Inc.). 
The 8 input CEL files (3 replicates of day 7 samples, 2 replicates of day 10 samples, and 3 replicates of 
day 14 samples) were analyzed to identify genes that were significantly differentially expressed or 
displayed significant differential alternative splicing between the groups of interest. Replicate 1 of day 
10 was removed due to poor data quality. 
For the tissue-specific exon expression analysis of the beta spectrin gene, we compared three 
replicates of erythroid day 14 to three replicates of the muscle tissue Exon Array data1. The splicing 
index1>l5 was calculated to create figures for the candidate genes showing alternative exon usage in the 
array data. 
The exon junction array contains probesets that were designed to interrogate both exons and the 
observed exon-exon junctions for approximately 35,000 genes in the human genome. The design uses 
transcript annotations from RefSeq, Ensembl, and Exonwalk. Approximately 250,000 exon clusters 
are represented. Additional details on the junction array design are included in the supplementary 
material. 
Labeled target generated from five biological replicates of total RNA extracted from day 7 and 
day 14 was hybridized to the junction array. Target was prepared using the same method as the Human 
Exon 1.0 ST arrays. One replicate of the day 14 samples was deemed an outlier and removed from 
subsequent analyses. Data from the junction arrays was processed using the Affymetrix Power Tools. 
Candidate alternative splicing events were established using the splicing index approach1. Each exon 
or junction probeset was analyzed independently. We then selected splicing events for which than one 
informative probeset showed a significant change in utilization between the day 7 and day 14 samples. 
In particular, we selected cassette exons that exhibited reciprocal behavior of the probeset specific to 
the skip junction and one or more of the probesets monitoring inclusion of the exon. Additional details 
regarding analysis of the junction array data is included in the supplementary material. 
Reverse transcription PCR 
Validation of splicing changes predicted by microarray experiments was performed by RT-PCR 
analysis of the same RNA samples used for the array hybridizations. Total RNA was DNase-ieated, 
and 1pg was used to synthesize first strand cDNA with Superscript I11 (Invitrogen) and random 
hexamer primers in a total volume of 20 p1. 1p1 of the cDNA was used for standard 20p1 total volume 
PCR reactions. 25 to 35 cycles of amplification were performed under the following ~onditi~ns:" 
denaturation for 30 s at 94OC; annealing for 30 s at 55OC; extension for 30 s at 72OC. Primer sequences 
~ 
are shown in Supplementary Table 1. PCR products were analyzed on 5% polyacrylamide gels. 
Densitometry was carried out to compare bands using Alpha Imager 2200 v. 5.5 (Alpha Innotech 
~ 
Gorp.). At least two replicates were used to validate the array predictions by RT-PCR, and the identity 
of all PCR fragments was confirmed by DNA sequence analysis. It is worth noting that alternative 
splicing events supported by reciprocal changes in probesets for both exon inclusion versus exclusion 
events had a higher validation rate than those predicted by only one or the other. ~ 
RESULTS 
Analysis of differentiation stage-specific alternative splicing switches in human erythroblasts 
Human ~ ~ 3 4 '  primary erythroid progenitors from growtb fa~tor-m~bilized peripheral blood can 
differentiate in culture and undergo many of the programmed changes in gene expression that are 
characteristic of late erythropoiesis16-18. To investigate changes in alternative splicing that' occur 
specifically in differentiating erythroblasts, we analyzed cultures highly enriched (2 97%) for erythroid 
cells as determined by FACS analysis using CD71 and glycophorin A antibodies (Figure 1A). RNA 
from cdls cultured for 7 days (basophilic erythroblasts) and 14 days (orthochromatic erythroblasts) was 
then examined by exon microarray analysis and by RT-PCR in order to identify changes in gene 
expression at the level of alternative pre-mRNA splicing. 
I 
A key alternative splicing event during late erythropoiesis involves protein 4.1K exon 16, which 
5,8,10 is excluded in early erythroblasts but. included efficiently in late erythroblasts (Figure 1A). 
Consistent with RNA studies, isoforms of 4.1R protein that include the exon 16-encoded peptide are 
increased in these  cell^^'^. To confirm that the exon 16 alternative splicing switch occurs during 
differentiation of these primary erythroid cultures, we used RT-PCR to assay the abundance s f  
transcripts that either include or exclude exon 16. Figure 1B shows that exon 16 was included much 
more efficiently in late erythroblasts (day 14) than in early erythroblasts (day 7). This result validates 
the use of these cultures for analysis of stage-specific splicing changes in late erythropoiesis. 
Exon microarray analysis of changes in exon expression during late erythroid differentiation 
To identie new cases of alternative splicing in differentiating erythroid cells, we assessed genome- 
wide changes in exon expression using the Affymetrix Human Exon 1.0 ST Array. This microarray was 
designed to be as inclusive as possible, containing probes designed to detect expression of virtually all 
known and predicted exons in the human genome1. We hybridized these arrays with probes prepared 
from erythroblast RNA at three stages of differentiation (basophilic, polychromatic, and orthochromatic 
erythroblasts) from three independent cultures. Array data from these three groups were then analyzed 
using XRAY software to look for differentiation-associated changes in expression, both at the level of 
whole transcripts and at the level of individual exons. For most comparisons, we focused on basophilic 
versus orthochromatic samples to maximize potential differences in gene expression. ~ 
First, gene-level changes in expression were deduced by combining the hybridization data for 
all informative probes from each annotated transcript. Previous studies have shown that differentiation 
in this erythroid culture system is characterized by increased expression of known red cell proteins, 
including band 3, ankyrin, and protein 4.1, whose mRNAs begins to accumulate around day 817. As 
expected, exon expression analysis confirmed the up-regulation of these transcripts, as well as others 
encoding enzymes involved in heme biosynthesis (e.g., ALAS2) and proteins associated with the 
I 
membrane skeletal network (e.g., EPB49, EPB42, AQPI, GYPB). Conversely, many other transcripts 
I 
exhibit a significant decrease in expression in late erythroblasts. For example, the transcript encoding 
HNRPAI, a negative regulator of 4.1 exon 16 splicing known to be down-regulated in late 
erythrobla~ts'~, was lower at late time points (e.g., day 14) compared to the early time point (day 7). 
Supplementary Tables 2 and 3 list the transcripts that show greater than two-fold increase or decrease 
in expression in early versus late erythroid progenitor cells. 
Next, to determine whether the exon array data could detect known alternative splicing events, 
we considered the case of beta spectrin (SPTB). Beta spectrin mRNAs are known to possess distinct 3' 
terminal exons in eythroid cells and in muscle cells, due to alternative splicing and alternative 
I 
polyadenylation (Figure 2, upper panel; ref. 19). Comparison of the new erythroid exon expression data 
to publicly available Exon Array data for human skeletal muscle' was performed using XRAY aLlysis 
software to identify predicted splicing differences. As expected, beta-spectrin ranked near the top of the 
list of genes predicted to splice differently in muscle versus erythroid cells. To visualize these 
differences, the array data was used to calculate the splicing index, a measure for detection of 
alternative splicing differences by identifying probesets that exhibit differential expression between 
RNA samples after normalizing for transcript levels (ref. 1 and supplementary information). The 
splicing index is shown in Figure 2 (lower panel). Probesets representing the 5' and central regions of 
the gene exhibited no significant differences in relative expression in erythroblasts versus muscle, as 
indicated by consistent values for the splicing index close to zero. In contrast, substantial differences 
were observed at the 3' end. The upward peak labeled "erythroid" indicates enriched expression of 
probesets corresponding to the known erythroid-specific 3' end, while the downward peak "muscle" 
represents probesets that map to the muscle-specific 3' exons and are under-expressed in erythroid 
RNA relative to their higher expression in muscle. This finding confirms exon array detection of a well- 
known erythroid-specific gene expression event. 1 
Identification of stage-specific changes in utilization of alternative first exons. 
Array data was next examined for evidence of differential exon expression in late erythropoiesis, as 
manifested by significant changes in probeset expression between basophilic (day 7) and 
orthochromatic (day 14) erythroblasts. After filtering out probesets with low expression and low 
variance, transcripts with highly significant differences in alternative splicing were manually inspected 
by mapping to the human genome to eliminate those with ambiguous transcript cluster assignments1. 
Transcripts that displayed consistent day 7 1 day 14 expression ratios across most of their probesets, but 
differed markedly in one discrete region, were chosen for further characterization. This process 
eliminated many transcripts with poor annotation, inconsistent probe behavior, and/or overly complex 
splicing patterns. 
Among the probesets exhibiting stage-specific changes in expression, several mapped to  the 5' 
ends of transcripts and were considered to be candidate alternative first exons. Many erythroid genes 
are known to possess alternative first exons3, but few have been analyzed for changes in expression 
during late erythropoiesis. RT-PCR analysis confirmed three examples of switches in alternative first 
exon usage that occur in late erythropoiesis (Figure 3, left). Gene models at the right depict 5' 
~ 
exonlintron structure of these genes, based on data from the Refseq track in the UCSC genome 
browser, and illustrate the predominant expression pattern at day 7 (black lines) and day 14 (red lines) 
that was deduced fiom array and PCR experiments. Two alternative 5' ends are shown for SLC12A6 
(KCC3, a KC1 co-transporter) and three each for GCNT2 (an acetylglucosaminyltransferase important 
in the formation of human blood group I antigen) and TNP02 (transportin-2). For each gene, PCR 
reactions were performed using multiple forward primers (one in each alternative 5' exon) and single 
reverse primer in the downstream constitutive exon ("exon 2"). Competitive PCR reactions of this 
nature have been used previously to detect variations in expression of terminal exons (e.g., ref. 20). The 
11 I 
I 
top panel shows the SLC12A6 transcript, for which exon microarray data indicated a stage-specific 
decrease in expression of exon 1B relative to exon IA, as cells differentiate from day 7 to 14. To 
validate this prediction, RT-PCR analysis was performed with two forward primers (in exons 1A and 
1B) and a single reverse primer (in exon 2). As shown in Figure 3B, the relative amounts of amplified 
exon 1B product declined significantly relative to that of exon lA, cod~rming the microarray 
prediction. 
Two additional examples of alternative first exon usage were similarly predicted by the exon 
array data and verified by RT-PCR, in the GCNT2 and TNP02 genes (Figure 3, middle and lower 
panels). PCR clearly showed a substantial difference in relative expression of alternative first exons 
between basophilic and orthochromatic erythroblasts for GCNT2, with exon 1A predominating at day 7 
and exon 1C relatively much more abundant at day 14. Exon 1B was barely expressed in these 
erythroblast cultures; however, it could be amplified efficiently from brain cDNA (lane br), providing 
further evidence for tissue-specific regulation of first exon usage in the GCNT2 gene. For TNP02, 
there was a substantial switch in relative use of exons 1A and 1B between day 7 and day 14 
erythroblasts (bottom panel). Relatively little expression exon 1C was observed, with only small 
amounts detected in day 14 erythroblasts and in brain. For both of these genes, the RT-PCR data was 
consistent with the exon microarray predictions and thus two independent assays confirm the switch in 
expression of alternative first exons. ~ 
Stage-specific switches in alternative pre-mRNA splicing of internal cassette exons 
The Human Exon 1.0 ST Array can also detect alternative splicing changes within internal regions of 
1,14,15 transcripts . We used this array in conjunction with a prototype exon junction array, which focuses 
on a smaller set of well-annotated exons, in order to identify additional splicing changes in 
differentiating erythroid cells. Junction probes provide additional information that can aid in predicting 
splicing differences between RNA samples, since a change in alternative splicing should yield reciprocal 
changes in intensity of junction probes for the exon skipping and exon inclusion event, respectively. 
Figure 4 illustrates detection of the protein 4.1R exon 16 splicing switch by the junction array. 
The structures of two Refseq transcripts that include or exclude exon 16 are shown in the lower part of 
the Figure, with the position of alternative exon 16 indicated by the arrow. The position of junction 
probesets exhibiting a significant change in expression, normalized to transcript levels, is shown above. 
~ 
The two probesets representing exon 16 inclusion products exhibited strong up-regulation in day 14 
orthochromatic erythroblasts (probeset ID 504900 for the exon 13/16 junction, p=7.5E-07, and probeset 
224956 for the exon 16/17 junction, p=1.6E-09). Importantly, the probeset interrogating the exon 16 
skipping event demonstrated a significant decrease in expression in these more mature cells (probeset 
ID 366937, spanning the exon 13/17 junction, p=1.2E-04). Thus, the reciprocal increase in inclusion 
probes and decrease in the exclusion probe validates the ability of the junction array to detect a known 
splicing switch, the activation of exon 16 splicing in late erythroblasts. 
Further analysis of junction array data predicted several novel erythroid stage-specific alternative 
splicing switches. All of these cases exhibited a significant decrease at day 14 in the junction probeset 
representing the exon skipping event, and a reciprocal increase for at least one probeset representing the 
alternative exon inclusion event. The diagram in Figure 5A illustrates schematically the locations of 
these diagnostic probesets for a model alternative splicing event. Table 1 summarizes hybridization data 
of specific probesets for six candidate stage-specific exons, and also provides some information 
regarding the identity of the genes / exons undergoing the putative splicing switches. In order to evaluate 
the performance of the microarray, we sought independent verification of these splicing predictions 
13 1 
using PCR methods to amplify across the relevant region of each mRNA using primers in the flanking 
exons. Alternative splicing switches should be manifested by changes in the relative amounts of exon 
inclusion/exon exclusion products when comparing PCR products derived from basophilic and 
orthochromatic erythroblast samples. As shown in Figure 5B, this was indeed the case, as six new exons 
were validated by RT-PCR analysis to have substantial erythroid stage-specific changes in alternative 
splicing in two independent biological replicates. In each case, consistent with the microarray 
predictions, the relative efficiency of alternative exon inclusion was higher in the more mature day 14 
(orthochromatic) erythroblasts. Control experiments confirmed the expected sequence of these PCR 
products, and demonstrated that exon inclusion:exclusion ratios were independent of PCR cycle number 
within the range examined (Supplementary Figure 1). The latter is an important criterion typically used 
22-25 in splicing studies to validate cell-specific differences in alternative splicing . Together, the 
combined analysis of erythroblast mRNA by exon microarrays and RT-PCR strongly supports the 
hypothesis that these splicing switches are bona Jide features of the gene expression program in late 
erythropoiesis. 
Effects of stage-specific splicing switches on protein structure 
In cases where alternative first exons contain coding information or influence expression of 
downstream coding sequences, switches in alternative first exon expression can directly impact N- 
terminal protein structure. The late erythroid switches in first exon use for SLC12A6 and GCNT2 both 
fall into this category, since these exons contain translation initiation sites. The GCNT2 gene has an 
unusual structure in which three long alternative first exons encode alternative but structurally similar N- 
terminal domains of -308 amino acids each26. Our finding that exon 1C represents the major isoform in 
late erythroblasts is consistent with previous reports that exon 1C is strongly expressed in terminally 
differentiating K562 cells2'. In contrast, first exons in the TNP02 gene do not possess start codons and 
thus switching does not affect protein structure. 
All of erythroid stage-specific splicing switches involve internal cassette exons that exhibit 
enhanced inclusion at day 14, relative to less efficient or undetectable inclusion at day 7. The exons 
switched on in late erythroblasts range in size from 66-1 14nt, significantly smaller than the average 
human exon but consistent with previous observations that alternative exons are generally shorter than 
a ~ e r a ~ e ~ ~ ? ~ ' .  In each case the splicing switch is within the coding portion of the transcript and thus it will 
alter the protein product. For PLDl (phospholipase Dl) and ARFIPl (arfaptinl, or ADP-ribosylation 
factor interacting protein l), the splicing switches are predicted to insert in-frame peptides of -3-4kDa, 
without alteration of C-terminal sequences. There are no obvious functional motifs encoded in these 
alternative peptides. Interestingly, ARFIPl has been reported to inhibit PLDl activity29, suggesting the 
possibility that splicing changes in both genes might coordinately affect some aspect of signaling or 
~ 
membrane trafficking. The four remaining splicing switches differ in that they should induce C-terminal 
alterations or truncations in the encoded proteins. In MBNL2 (muscleblind2, an RNA binding protein), 
the switch introduces a new penultimate coding exon that inserts a new peptide and also changes the 
reading frame. The resulting mRNA should terminate translation at an alternative site in the final exon. 
In three other genes, the inserted exon contains an in-frame stop codon so that the splicing switch will 
result in C-terminal truncations of the predicted protein product. This is the predicted outcome of 
splicing switches in HNRPLL (heterogeneous nuclear ribonucleoprotein L-like), SNRP70 (U1 small 
nuclear ribonucleoprotein 70K, a component of the U 1 snRNP), and ATP 1 1 C (ArPase class VI type 
11C). Whether the truncated proteins have any physiological role is unknown. However, since the 
truncations would delete one of the two RNA binding motifs in HNRPLL and half of the single RNA 
15 
binding domain in SNRP70, any function would be quite different from, and potentially antagonistic to, 
the full length proteins. Because MBNL2, HNRPLL, and SNRP70 have known or predicted affects on 
pre-mRNA splicing, these results suggest that alternative splicing of selected factors may potentially 
affect a wider range of RNA processing events in late erythropoiesis. 
DISCUSSION 
High-resolution analysis of the erythroid transcriptome provides new insights into the 
mechanisms by which gene regulatory mechanisms orchestrate expression of a highly dynamic 
proteome in a developmentally appropriate, tissue-specific manner. The current study complements and 
extends previous analyses of the erythroid t r a n s ~ r i ~ t o m e ' ~ ~ ~ ~  by exon-level analysis of switches in 
alternative splicing during late erythropoiesis. Based on the finding of several novel stage-specific 
splicing switches in erythroid gene expression, we propose the existence of an alternative splicing 
program that is essential for proper differentiation of late erythroid cells. All of the switches involve 
bonaJide splicing events that occur precisely at exon-intron boundaries of annotated exons, supporting 
the hypothesis that they represent programmed splicing changes rather than a general de-regulation of 
~ 
the splicing machinery in late erythropoiesis. Our results indicate that this program is comprised of 
distinct regulatory mechanisms involving transcription events at alternative promoters, and splicing 
events at internal alternative exons, as both processes contribute to modulation of gene expression in 
important ways that are generally not detectable by standard expression analysis. ~ 
Alternative first exons are common among erythroid genes 3,33,36-40 , and indeed among the whole 
spectrum of genes in the human genome34,35. In this report we show that switches in expression of 
alternative first exons can occur even late in erythroblast differentiation. Such changes can affect 
16 
protein levels quantitatively andlor qualitatively, depending on the relative expression levels of the 
transcripts and the location of translation start codons. Mechanistically, it is likely that these sktches 
are regulated at the transcriptional level, since alternative first exons generally possess their own 
promoters (e.g., ref. 33), but changes in mRNA stability of alternative isoforms could also play a role in 
some transcripts. Our finding that GCNT2 exon 1C represents the major isoform in late erythroblasts is 
consistent with previous reports that exon 1C is up-regulated in terminally differentiating K562 cells by 
activity of transcription factor CCAAWenhancer binding protein u (cIEBP~)~ ' .  The switches in 
SLC12A6 and TPN02 first exons could potentially be determined by a related mechanism, perhaps 
operating so as to allow the genes to escape downregulation of expression in late erythroblasts. 
A second class of gene expression changes involves internal cassette exons that are regulated at 
the level of alternative pre-mRNA splicing. Interestingly, in each of the six new cases described here, 
alternative exon inclusion was increased in late erythroblasts. This observation suggests that a common 
pathway or shared splicing program may be coordinating these splicing events. Preliminary analysis of 
potential splicing regulatory motifs has revealed that five of the six stage-specific exons possess in the 
flanking proximal introns a highly specific UGCAUG binding site for the alternative splicing regulator 
Fox-2 (data not shown). This frequency is much higher than expected by chance and is consistent with 
a coordinating role of Fox-2 in mediating some of these late erythroid alternative splicing switches. 
Indeed, Fox-2 has already been reported to play an important role in activating the protein 4.1R exon 16 
splicing swi t~h '~ , ' ~ .  Moreover, Fox-11Fox-2 binding sites are highly over-represented in the introns 
near many muscle-enriched exons14 , and also near brain-enriched ex on^^','^, but not near nontissue- 
specific alternative exons or constitutive exons. However, the erythroid-, muscle- and brain-enriched 
exon datasets identified in these studies are largely unique. We speculate that Fox proteins are 
necessary to activate splicing switches of many tissue-specific exons, but not sufficient to determine the 
17 
spatial or temporal patterns of these switches. Tissue-specific differences in Fox protein structure 
(mediated by regulated alternative splicing of the Fox pre-mRNAs them~elves~~)  or in the complement 
of putative Fox interacting proteins (e.g., ref. 44), are presumably required to execute the appropriate 
alternative splicing programs through development. Future studies will be required to test this 
hypothesis experimentally. 
It is noteworthy that three of the alternative splicing switches in late erythropoiesis involve exons 
containing premature termination codons (PTC), such that the resulting mRNAs would encode truncated 
proteins. While it is possible that the truncated proteins have unique functions, recent studies suggest an 
alternative purpose for this type of regulated splicing. Premature stop codons often induce rapid mRNA 
degradation via nonsense mediated decay (NMD), and alternative splicing coupled to nonsense mediated 
decay can represent an evolutionarily conserved strategy for regulating gene e ~ ~ r e s s i o n ~ ~ ~ ' ~ .  This 
process, termed "regulated unproductive splicing and translation" (RUST), provides a control 
mechanism for modulating gene expression by regulating the balance between functional mRNAs that 
encode full length proteins and PTC-containing mRNAs that do not. RUST has been demonstrated most 
convincingly in the case of RNA binding proteins with roles in pre-mRNA and it may 
therefore be very relevant that two of the PTC-containing erythroid splicing events involve RNA 
binding proteins (HNRPLL and SNRP70). ~ 
The modest number of alternative splicing switches identified in this study is comparable to 
other recent reports15725, but likely represents only a fraction of the total changes in splicing that occur in 
differentiating erythroblasts. Here we examined only splicing switches that occur in late stages of 
erythropoiesis; only annotated alternative splicing events are represented on the microarray; and we can 
detect only exons represented by "good" oligonucleotide probes that hybridize well under standard 
conditions. Moreover, given the observation that some splicing switches introduced premature stop 
codons, NMD may have masked splicing changes that result in rapidly degraded mRNAs. We anticipate 
that further advances in array technology, together with application of high throughput sequencing32 and 
I 
analyses of earlier stages of erythroid differentiation, will lead to discovery of many additional switches 
in promoter use and alternative splicing that have important implications for erythroid physiology. 
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FIGURE LEGENDS 
Figure 1. Stage-specific switch of protein 4.1R exon 16 splicing in highly purified erythroblast 
cultures. A. FACS analysis of day 7 erythroblasts from three different preparations indicates purity is 
>97%, based on expression of erythroid markers for Glycophorin A and CD71. Quantitative analysis 
demonstrated erythroblast purities as follows: prep. #1,97%; prep. #2, 97%; and prep. #3,99%. B. RT- 
I 
I 
PCR scheme employed to analyze 4.1R pre-mRNA splicing in early (day 7) and late erythroblasts (day 
14), using primers in the nearest constitutive exons 13 and 17. Gel image shows primarily exclusion of 
exon 16 in early erythoblasts (lower band), while substantial inclusion of exon 16 was observed in late 
erythroblasts (upper band). Alternative exons 14 and 15 are not expressed in erythroid cells. ~ 
Figure 2. Exon array detection of erythroid-specific beta spectrin mRNA 3' end. Upper panel 
depicts the exon structure of human beta spectrin transcripts in muscle versus erythroid cells, which 
express distinct 3' terminal exons. Lower panel shows the splicing index of probesets across the full 
length of the beta spectrin gene. Numbers along the horizontal axis represent probeset IDS. Positive 
values for the splicing index represent higher relative probeset expression in erythroblasts, while 
negative values indicate higher relative expression in muscle. The significant upward peak maps to the 
known erythroid-specific 3' end, while the downward peak represents the muscle-specific 3' end. 
Figure 3. Stage-specific change in expression of alternative first exons. A. Splicing index shows 
normalized changes in probeset expression along the entire SLC12A6 transcript for day 10 (blue 
curve) and day 14 erythroblasts (red curve), relative to expression at day 7 (black line). Results show 
l 
a stage-dependent increase in expression of probesets representing the 1A region (boxed), and a 
I 
I 
decrease in expression of probesets for exon 1B. B. RT-PCR validation of exon array predictions for 
SLC12A6 and two additional genes. Shown are gels of PCR products validating alternative splicing 
switches in first exon expression (left) and diagrams of the relevant pre-mRNA regions (right). Black 
arrow / black lines indicate predominant pattern in day 7 erythroblasts, and red arrow / red lines 
indicate predominant pattern in day 14 erythroblasts. Alternative first exons are indicated by IA, lB, 
1C and a shared constitutive exon indicated as exon 2. Common names of the alternatively spliced 
transcripts are as follows: SLC12A6, KC1 co-transporter 3 (KCC3); TNP02, transportin 2 (a nuclear 
import protein); GCNT2, glucosaminyl (N-acetyl) transferase 2 (generates the branched chain 
carbohydrate structure that constitutes the I antigen). 
Figure 4. Exon junction array detection of the 4.1R exon 16 splicing switch. Probesets in the exon 
16 region that exhibit significant changes in relative expression between day 7 and day 14 were mapped 
~ 
to the human genome using the UCSC BLAT alignment tool. Bottom panel shows the exon structure 
of the two mRNA isoforms expressed from the 4.1R gene; arrow indicates alternative exon 16. Upper 
panel shows that probesets interrogating the exon 16 inclusion event were up-regulated at day 14, while 
a reciprocal decrease in expression of the exon 13- 17 skipping event was observed. RT-PCR validation 
of this splicing switch is shown in Figure 1. Alternative exons 14 and 15 are not expressed in these 
I 
cultures. 
Figure 5. Novel stage-specific alternative splicing switches in erythroid genes. A. General scheme 
for detection of alternative splicing of a pre-mRNA (left) into the mRNA isoform including the 
alternative exon (upper right) or the mRNA skipping this exon (lower right). Diagnostic isoform- 
specific microarray probes are indicated above the spliced mRNAs, while PCR primers used for 
validation are shown below the mRNAs (arrows). In addition, there are exon probes for the first and 
third exons that hybridize equally to both isoforms and are useful for determining overall transcript 
levels. B. Shown are gels of PCR products validating alternative splicing switches in late erythropoiesis 
(left) and diagrams of the relevant pre-mRNA regions (right). Gels demonstrate substantial increases in 
26 1 
exon inclusion products (upper bands, indicated by arrows), relative to exon skipping products (lower 
bands), at day 14. The deduced splicing patterns are indicated at the right, with black lines indicating 
major splice patterns at day 7 and red lines indicating predominant splice pattern at day 14. Asterisks 
indicate positions of stop codons (not shown for ARFIPl and PLDl because they are located farther 
downstream). Common names of the alternatively spliced transcripts are as follows: HNRPLL, 
heterogeneous nuclear ribonucleoprotein L-like (an hnRNP protein); SNRP70, U1 small nuclear 
ribonucleoprotein 70K (a component of the U1 snRNP); MBNL2, muscleblind 2 (RNA binding 
proteins with known splicing regulatory activity); ATP 1 1 C, ATPase class VI type 1 1 C; ARFIP 1, ADP- 
ribosylation factor interacting protein 1 ; PLDl, phospholipase Dl.  
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